Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5Lymphoid 4Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma 3Virus Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lamivudine × Lymphoid × Clear all
NCT01528865 2016-03-11

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Virus Diseases

NCT00041327 2016-02-03

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

AIDS Malignancy Consortium

Phase 2 Completed
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01210287 2014-01-08

IHBVRL

Fudan University

Phase 2/3 Unknown
110 enrolled
Lymphoid

Lymphoma

NCT01914744 2013-08-02

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Fudan University

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡